您的位置: 首页 > 2016年1月 第47卷 第1期 > 文字全文
2023年7月 第38卷 第7期11
目录

B超弹性成像监测下应用吉西他滨耐药乳腺癌细胞4T1构建裸鼠乳腺癌肝转移模型

Application of a gemcitabine-resistant variant of breast cancer cell line (4T1/Gem) to construct nude mouse models of breast cancer with hepatic metastasis under ultrasonic elastography

来源期刊: 广州医药 | 49-52 发布时间:2021-11-30 收稿时间:2025/11/13 17:06:08 阅读量:14
作者:
关键词:
乳腺癌吉西他滨耐药P-gp蛋白裸鼠成瘤
Breast cancerGemcitabineDrug-resistantP-gp proteinForming tumor in nude mice
DOI:
10.3969/j.issn.1000-8535.2016.01.017
收稿时间:
2015-10-15 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 构建吉西他滨耐药乳腺癌细胞4T1耐药株并建立裸鼠乳腺癌肝转移模型。方法 采用低浓度加量持续诱导法,诱导吉西他滨耐药乳腺癌细胞4T1耐药株,命名为4T1/Gem;CCK-8法测定4T1与4T1/Gem细胞的增殖抑制率,计算耐药指数; Western blot法检测细胞P-gp蛋白表达;B超引导下注射4T1/Gem细胞悬液诱导裸鼠肝脏成瘤;HE染色观察肿瘤组织病理情况,免疫组化法检测瘤组织ER、PR、HER2、Ki-67和P-gp蛋白的表达。结果 经过14个月的诱导成功建立4T1/Gem细胞株,可在含40 μg/mL的Gem培养液中稳定生长。4T1/Gem细胞耐药指数为4T1细胞的788.547倍。与亲代相比,4T1/Gem处于G1期和G2期的细胞增加,S期细胞减少;上调P-gp蛋白的表达。4T1/Gem细胞成功建立裸鼠乳腺癌肝转移模型,瘤组织中ER、PR、HER2蛋白阴性表达,Ki-67阳性10%和P-gp蛋白阳性表达。结论 成功构建吉西他滨耐药乳腺癌细胞4T1耐药株并建立裸鼠乳腺癌肝转移模型,为开发治疗乳腺癌肝转移化疗耐药的药物提供实验基础。
Objective To construct a gemcitabine-resistant variant of the breast cancer cell line (4T1/Gem) and establish a nude mouse model of breast cancer with hepatic metastatic. Methods A gemcitabine-resistant variant of the breast cancer 4T1 cell line was induced by gradually increasing the concentration of gemcitabine; this variant is referred to in this study as 4T1/Gem. The proliferation suppression rates of 4T1 and 4T1/Gem cells were determined by using the CCK-8 essay to evaluate the drug resistance indices of the cell lines. Western blot analysis was used to detect P-gp protein expression. Under ultrasonography, a 4T1/Gem cell suspension was injected into nude mice to induce liver tumors. H&E staining was used to observe tumor pathology, and immunohistochemistry was used to detect the expression of ER, PR, HER-2, Ki-67, and P-gp. Results After 14 months of induction, a 4T1/Gem cell line is established successfully. The cell line can grow stably in culture liquid containing 40 μg/ml gemcitabine. The drug resistance index of 4T1/Gem is 788.547. Compared with the 4T1 cell line, the 4T1/Gem cell line can upregulate P-gp protein expression and successfully establish a nude mouse model of breast cancer with hepatic metastatic. ER, PR, and HER-2 proteins exhibit negative expression in the tumor tissue. The positive expression of P-gp and 10% of Ki-67 proteins is also observed. Conclusion This study successfully constructs a gemcitabine-resistant variant of the breast cancer cell line (4T1/Gem)and establishes a nude mouse model of breast cancer with hepatic metastatic, thereby providing an experimental basis for developing and treating a drug-resistant variant of breast cancer.
1、 KIM MP, GALLICK GE. Gemcitabine resistance in pancreatic cancer: picking the key players[J]. Clin Cancer Res, 2008, 14(5): 1284-1285. KIM MP, GALLICK GE. Gemcitabine resistance in pancreatic cancer: picking the key players[J]. Clin Cancer Res, 2008, 14(5): 1284-1285.
2、 ANDERSSON R, AHO U, NILSSON BI, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions [J]. Scand J Gastroenterol, 2009,44(7): 782-786. ANDERSSON R, AHO U, NILSSON BI, et al. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions [J]. Scand J Gastroenterol, 2009,44(7): 782-786.
3、 BERGMAN AM, PINEDO HM, PETERS G J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine)[J]. Drug Resist Updat, 2002, 5(1): 19-33. BERGMAN AM, PINEDO HM, PETERS G J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine)[J]. Drug Resist Updat, 2002, 5(1): 19-33.
4、 MALLINI P, LENNARD T, KIRBY J, et al. Epithelial-tomesenchymal transition: what is the impact on breast cancer stem cells and drug resistance [J]. Cancer Treat Rev, 2014,40(3): 341-348. MALLINI P, LENNARD T, KIRBY J, et al. Epithelial-tomesenchymal transition: what is the impact on breast cancer stem cells and drug resistance [J]. Cancer Treat Rev, 2014,40(3): 341-348.
5、 HAGMANN W, JESNOWSKI R, LOHR JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells[J]. Neoplasia, 2010, 12(9): 740-747. HAGMANN W, JESNOWSKI R, LOHR JM. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells[J]. Neoplasia, 2010, 12(9): 740-747.
6、 SINGH A, SETTLEMAN J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer [J]. Oncogene, 2010, 29(34): 4741-4751. SINGH A, SETTLEMAN J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer [J]. Oncogene, 2010, 29(34): 4741-4751.
7、 ZHANG J, WANG Z, HU X, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer [J]. Int J Cancer, 2015, 136(1): 204-211. ZHANG J, WANG Z, HU X, et al. Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer [J]. Int J Cancer, 2015, 136(1): 204-211.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录